港交所(00388.HK):第四季上市活动显着回升 新上市公司数目为历年最多
港交所(00388.HK)公布2019年回顾,指今年港交所预计将再登全球首次公开集资排名榜首,为2010年来第六度称冠。自9月以来上市活动亦显着回升,第四季新上市公司数目为历年最多,并迎来多宗全球最大型的上市,印证了香港市场对全球发行人的强大吸引力。
公布指,过去一年尽管面临严峻的环球政治及宏观经济环境,港交所业务仍然持续表现良好,1月至9月期间公司收入仍创新高,增长动力来自包括交易後业务、大宗商品及科技业务等。展望2020年,港交所将继续专注落实三年战略规划,捕捉区内外各项发展机遇,以实现成为「国际领先的亚洲时区交易所」的愿景。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.